187 related articles for article (PubMed ID: 9412812)
21. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
[TBL] [Abstract][Full Text] [Related]
22. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
23. P53 accumulation in precursor lesions and early stages of bladder cancer.
Schmitz-Dräger BJ; van Roeyen CR; Grimm MO; Gerharz CD; Decken K; Schulz WA; Bültel H; Makri D; Ebert T; Ackermann R
World J Urol; 1994; 12(2):79-83. PubMed ID: 8087143
[TBL] [Abstract][Full Text] [Related]
24. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
27. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
28. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM; Spicer JF; Barnes DM; Lane DP
Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
[TBL] [Abstract][Full Text] [Related]
29. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
30. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
31. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
32. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
33. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis.
Li XJ; Murai M; Koyama T; Wang DY; Hashimoto K
Jpn J Cancer Res; 2000 May; 91(5):492-8. PubMed ID: 10835493
[TBL] [Abstract][Full Text] [Related]
34. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis.
Blok P; Craanen ME; Dekker W; Offerhaus GJ; Tytgat GN
J Pathol; 1998 Sep; 186(1):36-40. PubMed ID: 9875138
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma.
Ioachim E; Charchanti A; Stavropoulos NE; Skopelitou A; Athanassiou ED; Agnantis NJ
Histol Histopathol; 2000 Jul; 15(3):721-7. PubMed ID: 10963116
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
37. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
38. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
40. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
